
Supriya Lifescience Limited has informed the Exchange regarding a press release dated December 09, 2024, titled "Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing".
Filed with NSE ·

Supriya Lifescience Limited has informed the Exchange regarding a press release dated December 09, 2024, titled "Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing".
6ix hasn’t read this filing yet.
Supriya Lifescience Limited on 6ix
Follow Supriya Lifescience into a list and get an email when it puts out news.
Follow Supriya Lifescience